Joy Harris’ Post

ADVI Health's team of leading #marketaccess and #biopharma experts understand and translate the impact of policy implementations for our clients and their product lifecycle. We form comprehensive and informed solutions based on our client's needs to ensure strategic guidance while working closely with #pharmaceutical and device manufacturers, and our collaborative and partner-based approach across all ADVI solutions is what allows us to ensure client success. Learn more about our market access and biopharma expertise: https://lnkd.in/eCh3_sQx #ADVISolutionSpotlight

Fierce Pharma's latest report unveils the anticipated pharmaceutical shifts of 2024. Delve into the impending generics and biosimilars competition facing industry leaders. From industry giants to niche players, discover the impending transformations shaping the healthcare landscape. #KrugAssociates #PatentExpirations #HealthcareTrends #PharmaInsights #HealthcareShifts

ZS’s Cody Powers and Josh Hattem share data on pharma launches and approvals and why clinical trials continue to decline. Read our first portfolio and business development quarterly report: #pharma #pharmatrends #ZSpharmalaunchreport

ZS’s Cody Powers and Josh Hattem share data on pharma launches and approvals and why clinical trials continue to decline. Read our first portfolio and business development quarterly report: #pharma #pharmatrends #ZSpharmalaunchreport

💡 Join Syneos Health for an informative webinar focused on strategies and insights needed to comply with the Inflation Reduction Act (IRA) and capitalize on its new provisions for drug development, pricing, and market access in the biopharmaceutical industry. Attendees will: ✅ Learn new compliance requirements and regulatory adjustments ✅ Explore the IRA's impact on drug development, pricing, and market access ✅ Discover strategic planning techniques to drive innovation while maintaining compliance 📌 Learn more + register here: https://buff.ly/3xRHhR8 🌟 Featured speakers: Tiffany M. Peter Yixiao Zou, Ph.D. #DrugDevelopment #PharmaceuticalManufacturing #Commercialization #HEOR #MarketAccess

What’s the hardest part about reverification season for your team? A) Lack of available information B) Time-consuming manual tasks C) Lack of personnel D) All of the above Our eMedBV solution can solve all these issues and more for #pharmaceutical teams. By partnering with us, you can create option E: “None of these.” Sign up for our solution today to glide through reverification season: https://lnkd.in/gvqVKiDJ Learn more: https://lnkd.in/e5Q-Q38G

Navigating the realm of pharmaceutical exclusivity, this report delves into the latest developments featuring Bristol Myers Squibb, Biogen, Novo Nordisk, Astellas, and Novartis, showcasing their blockbuster medications and storied histories. Additionally, it sheds light on companies such as PTC Therapeutics, Organon, Supernus, CSL, and Bausch + Lomb, who are poised to encounter significant potential losses in exclusivity throughout 2024. Embark on a journey through the evolving landscape of pharmaceuticals, tracing the path from exclusivity to new horizons. https://lnkd.in/dhvbzQnp Making changes? Let's have a conversation. At #SECORA our methodologies are proven in success to accelerate operational distinction in highly regulated industries. We have methods that address: Process Design & Optimisation, Lean & CIP Implementation, Project & Launch Management, Organization Development, Restructuring and Sustainability, and Supply Chain & Development. Visit www.secora.de for more info.

Every market is different, even if geographically close! Launch benchmarks can help tremendously. Register and dial in to our upcoming launch webinar with experts from Merck (MSD), BMS, Sanofi and Novartis to learn how to prioritize for launch! #pharmamarketing

Join our webinar and find out how to set your priorities right for a successful launch of your drug!

It's interesting to see that the local context of markets pharma companies are launching their new products in is also traceable in the perceptions of HCPs in those markets on common launch KPIs such as awareness or product familiarity. At Trilations, we support pharma clients with strategic insights that are data-driven. This includes providing benchmarks of historic succesful launches to compare to when preparing your market entry. Want to learn more? Let's get in touch.